Celyad Oncology S.A.
CYAD.BR · BRU
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €15,567 | €29,497 | €6,945 | €11,251 |
| - Cash | €790 | €4,200 | €6,229 | €7,004 |
| + Debt | €831 | €17,536 | €989 | €902 |
| Enterprise Value | €15,608 | €42,833 | €1,705 | €5,149 |
| Revenue | €14 | €172 | €14 | €58 |
| % Growth | -91.9% | 1,128.6% | -75.9% | – |
| Gross Profit | -€198 | -€52 | €5 | €33 |
| % Margin | -1,414.3% | -30.2% | 35.7% | 56.9% |
| EBITDA | -€3,609 | -€2,602 | -€2,789 | -€4,468 |
| % Margin | -25,775% | -1,512.8% | -19,921.4% | -7,703.4% |
| Net Income | -€3,700 | -€2,779 | -€3,044 | -€4,708 |
| % Margin | -26,428.6% | -1,615.7% | -21,742.9% | -8,117.2% |
| EPS Diluted | -0.089 | -0.067 | -0.12 | -0.16 |
| % Growth | -33.2% | 44.1% | 25% | – |
| Operating Cash Flow | €0 | -€2,849 | -€2,831 | -€6,871 |
| Capital Expenditures | €0 | -€118 | €0 | -€583 |
| Free Cash Flow | €0 | -€2,849 | -€2,831 | -€7,454 |